Angiogenesis and other markers for prediction of survival in metastatic renal cell carcinoma

References

• Skinner DG, Colvin RB, Vermillion CD, Pfister RC, Leadbetter WF. Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer 1971; 28: 1165–77
   PubMed Web of Science ®Google Scholar
• Bukowski RM. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer 1997; 80: 1198–220
   PubMed Web of Science ®Google Scholar
• Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994; 79: 185–8
   PubMed Web of Science ®Google Scholar
• Ryan HE, Poloni M, McNulty W, Elson D, Gassmann M, Arbeit JM, et al. Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res 2000; 60: 4010–5
   PubMed Web of Science ®Google Scholar
• Marti HH. Angiogenesis—a self-adapting principle in hypoxia. EXS 2005; 94: 163–80
   PubMedGoogle Scholar
• Jacobsen J, Rasmuson T, Grankvist K, Ljungberg B. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 1999; 163: 343–7
   Web of Science ®Google Scholar
• Meunier-Carpentier S, Dales JP, Djemli A, Garcia S, Bonnier P, Andrac-Meyer L, et al. Comparison of the prognosis indication of VEGFR-1 and VEGFR-2 and Tie2 receptor expression in breast carcinoma. Int J Oncol 2005; 26: 977–84
   PubMed Web of Science ®Google Scholar
• Rasmuson T, Grankvist K, Jacobsen J, Ljungberg B. Impact of serum basic fibroblast growth factor on prognosis in human renal cell carcinoma. Eur J Cancer 2001; 37: 2199–203
   PubMed Web of Science ®Google Scholar
• Ljungberg B, Rasmuson T, Grankvist K. Erythropoietin in renal cell carcinoma: evaluation of its usefulness as a tumor marker. Eur Urol 1992; 21: 160–3
   PubMed Web of Science ®Google Scholar
• Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, et al. The Heidelberg classification of renal cell tumors. J Pathol 1997; 183: 131–3
   PubMed Web of Science ®Google Scholar
• De Riese W, Goldenberg K, Allhoff E, Stief C, Schlick R, Liedke S, et al. Metastatic renal cell carcinoma (RCC): spontaneous regression, long-term survival and late recurrence. Int Urol Nephrol 1991; 23: 13–25
   PubMedGoogle Scholar
• Thoroddsen A, Gudbjartsson T, Jonsson E, Gislason T, Einarsson GV. Operative mortality after nephrectomy for renal cell carcinoma. Scand J Urol Nephrol 2003; 37: 507–11
   PubMed Web of Science ®Google Scholar
• Swanson DA, Borges PM. Complications of transabdominal radical nephrectomy for renal cell carcinoma. J Urol 1983; 129: 704–7
   PubMed Web of Science ®Google Scholar
• Minasian LM, Motzer RJ, Gluck L, Mazumdar M, Vlamis V, Krown SE. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 1993; 7: 1368–75
   Google Scholar
• Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004; 171: 1071–6
   PubMed Web of Science ®Google Scholar
• Wikström P, Lissbrant IF, Stattin P, Egevad L, Bergh A. Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate 2002; 51: 268–75
   PubMed Web of Science ®Google Scholar
• Delahunt B, Bethwaite PB, Thornton A. Prognostic significance of microscopic vascularity for clear cell renal cell carcinoma. Br J Urol 1997; 80: 401–4
   PubMedGoogle Scholar
• Jacobsen J, Grankvist K, Rasmuson T, Bergh A, Landberg G, Ljungberg B. Vascular endothelial growth factor protein expression in human renal cell carcinoma. BJU Int 2004; 93: 297–302
   PubMed Web of Science ®Google Scholar
• Harada Y, Ogata Y, Shirouzu K. Expression of vascular endothelial growth factor and its receptor KDR (kinase domain-containing receptor)/Flk-1 (fetal liver kinase-1) as prognostic factors in human colorectal cancer. Int J Clin Oncol 2001; 6: 221–8
   PubMedGoogle Scholar
• Lee YS, Vortmeyer AO, Lubensky IA, Vogel TW, Ikejiri B, Ferlicot S, et al. Coexpression of erythropoietin and erythropoietin receptor in von Hippel-Lindau disease-associated renal cysts and renal cell carcinoma. Clin Cancer Res 2005; 11: 1059–64
   PubMed Web of Science ®Google Scholar
• Ljungberg B, Landberg G, Alamdari F. Factors of importance for prediction of survival in patients with metastatic renal cell carcinoma, treated with or without nephrectomy. Scand J Urol Nephrol 2000; 34: 246–51
   PubMed Web of Science ®Google Scholar
• Leibovich BC, Han KR, Bui MH, Pantuck AJ, Dorey FJ, Figlin RA, et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003; 98: 2566–75
   PubMed Web of Science ®Google Scholar
• Golimbu M, Joshi P, Sperber A, Tessler A, Al-Askari S, Morales P. Renal cell carcinoma: survival and prognostic factors. Urology 1986; 27: 291–301
   PubMed Web of Science ®Google Scholar
• Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said JW, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002; 20: 4559–66
   PubMed Web of Science ®Google Scholar
• Neves RJ, Zincke H, Taylor WF. Metastatic renal cell cancer and radical nephrectomy: identification of prognostic factors and patient survival. J Urol 1988; 139: 1173–6
   PubMed Web of Science ®Google Scholar
• Krishnamurthi V, Novick AC, Bukowski RM. Efficacy of multimodality therapy in advanced renal cell carcinoma. Urology 1998; 51: 933–7
   PubMed Web of Science ®Google Scholar
• Tanguay S, Pisters LL, Lawrence DD, Dinney CP. Therapy of locally recurrent renal cell carcinoma after nephrectomy. J Urol 1996; 155: 26–9
   PubMed Web of Science ®Google Scholar